enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Acute lymphoblastic leukemia - Wikipedia

   en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia

   Brexucabtagene autoleucel (Tecartus) was approved for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in October 2021. [ 71 ] [ 72 ] Each dose of brexucabtagene autoleucel is a customized treatment created using the recipient's own immune system to help fight the lymphoma. [ 73 ]

3. Obecabtagene autoleucel - Wikipedia

   en.wikipedia.org/wiki/Obecabtagene_autoleucel

   Obecabtagene autoleucel, sold under the brand name Aucatzyl, is an anti-cancer medication used for the treatment of acute lymphoblastic leukemia. [1] [2] It is a CD19-directed genetically modified autologous T-cell immunotherapy.

4. T-cell acute lymphoblastic leukemia - Wikipedia

   en.wikipedia.org/wiki/T-cell_acute_lymphoblastic...

   Currently, standard treatment for T-cell acute lymphoblastic leukemia (T-ALL) involves long-term chemotherapy and medication to prevent or treat side effects associated with low white blood cell counts resulting from intensive chemotherapy regimens. The treatment typically occurs in three stages: induction, consolidation, and maintenance. [3]

5. Calaspargase pegol - Wikipedia

   en.wikipedia.org/wiki/Calaspargase_pegol

   Calaspargase pegol, sold under the brand name Asparlas, is a medication for the treatment of acute lymphoblastic leukemia (ALL). It is approved in the United States as a component of a multi-agent chemotherapeutic regimen for ALL in pediatric and young adult patients aged one month to 21 years. [5]

6. Tisagenlecleucel - Wikipedia

   en.wikipedia.org/wiki/Tisagenlecleucel

   Tisagenlecleucel is indicated for the treatment of those under 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse; or adults with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma ...

7. Blinatumomab - Wikipedia

   en.wikipedia.org/wiki/Blinatumomab

   In July 2014, the FDA granted breakthrough therapy status to blinatumomab for the treatment of acute lymphoblastic leukemia (ALL). [12] In October 2014, Amgen's Biologics License Application for blinatumomab was granted priority review designation by the FDA, thus establishing a deadline of 19 May 2015, for completion of the FDA review process ...